Jarvi Mark T, Niedre Mark J, Patterson Michael S, Wilson Brian C
Department of Medical Biophysics, Ontario Cancer Institute and University of Toronto, Toronto, Ontario, Canada.
Photochem Photobiol. 2006 Sep-Oct;82(5):1198-210. doi: 10.1562/2006-05-03-IR-891.
As photodynamic therapy (PDT) continues to develop and find new clinical indications, robust individualized dosimetry is warranted to achieve effective treatments. We posit that the most direct PDT dosimetry is achieved by monitoring singlet oxygen (1O2), the major cytotoxic species generated photochemically during PDT. Its detection and quantification during PDT have been long-term goals for PDT dosimetry and the development of techniques for this, based on detection of its near-infrared luminescence emission (1270 nm), is at a noteworthy stage of development. We begin by discussing the theory behind singlet-oxygen luminescence dosimetry (SOLD) and the seminal contributions that have brought SOLD to its current status. Subsequently, technology developments that could potentially improve SOLD are discussed, together with future areas of research, as well as the potential limitations of this method. We conclude by examining the major thrusts for future SOLD applications: as a tool for quantitative photobiological studies, a point of reference to evaluate other PDT dosimetry techniques, the optimal means to evaluate new photosensitizers and delivery methods and, potentially, a direct and robust clinical dosimetry system.
随着光动力疗法（PDT）不断发展并发现新的临床适应症，有必要进行可靠的个体化剂量测定以实现有效的治疗。我们认为，最直接的PDT剂量测定是通过监测单线态氧（1O2）来实现的，单线态氧是PDT过程中光化学产生的主要细胞毒性物质。在PDT期间对其进行检测和定量一直是PDT剂量测定的长期目标，基于对其近红外发光发射（1270 nm）的检测来开发相关技术目前正处于一个值得关注的发展阶段。我们首先讨论单线态氧发光剂量测定法（SOLD）背后的理论以及使SOLD达到当前状态的开创性贡献。随后，将讨论可能改善SOLD的技术发展、未来的研究领域以及该方法的潜在局限性。我们通过审视未来SOLD应用的主要方向来得出结论：作为定量光生物学研究的工具、评估其他PDT剂量测定技术的参考点、评估新的光敏剂和给药方法的最佳手段，以及潜在地作为一种直接且可靠的临床剂量测定系统。
